Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,697 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type-2 Diabetes Clear all
Completed Phase 3 Interventional Results available

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

NCT00082381
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide (AC2993), Insulin glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
21
States / cities
San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 23, 2026, 1:27 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Empathy in Action: Sunshine Calls for Life With Diabetes

NCT05173675
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Mental Health, Health Behavior
Interventions
Empathy in Action for life with diabetes., Control Phase 2 Materials Only
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Austin, Texas • Bastrop, Texas • Cedar Park, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

NCT01843881
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exendin 9, 39, Placebo
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 2 Interventional

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

NCT03317028
View directory record Official record
Conditions
T2DM With Inadequate Glycemic Control
Interventions
CS02 tablet and placebo tablet
Drug
Lead sponsor
Center Laboratories, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Little Rock, Arkansas • Coral Gables, Florida • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 1:27 PM EDT
Completed No phase listed Observational

Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

NCT05577728
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
New use of semaglutide injection, New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices

NCT04020822
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Guardian Sensor (3)
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Medical College of Georgia PLAY Project: Exercise Dose and Insulin Sensitivity in Obese Children

NCT00108901
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Prevention, Executive Function (Cognition)
Interventions
Aerobic exercise program
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years to 11 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 4 Interventional

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

NCT00101751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, dietary regimen
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 23, 2026, 1:27 PM EDT
Completed No phase listed Observational

Sleep Disordered Breathing and Diabetes

NCT00901472
View directory record Official record
Conditions
Type 2 Diabetes, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

NCT03552757
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide), Placebo II (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
50
States / cities
Buena Park, California • Concord, California • Fresno, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 3 Interventional

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

NCT00138619
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
478 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Intervention in Diabetes Self-Management

NCT01182701
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cognitive behavioral training
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 76 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 2 Interventional

NEW DAY: Nutrition, Exercise, Weight Loss, Diabetes And You

NCT00007800
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Behavioral Group Weight Loss Intervention, Motivational Interviewing
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
19 Years and older · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Oct 23, 2026, 1:27 PM EDT
Active, not recruiting Not applicable Interventional

PA Moves Trial - Patient Participants

NCT05227105
View directory record Official record
Conditions
Overweight or Obesity, Diabetes Mellitus, Type 2, Physical Inactivity
Interventions
Physical Activity, Delayed intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 1:27 PM EDT
Completed No phase listed Observational

CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target

NCT01548222
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

NCT00643851
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 23, 2026, 1:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reduce Obesity and Diabetes

NCT00954577
View directory record Official record
Conditions
Type 2 Diabetes, Pediatric Obesity, Dyslipidemia
Interventions
Nutrition, health, and exercise education
Behavioral
Lead sponsor
Academy for Medical Development and Collaboration, New York
Other
Eligibility
10 Years to 15 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
5
States / cities
Brooklyn, New York • Manhasset, New York • Mineola, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00286494
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and pioglitazone, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Multidisciplinary Team Approach: Working Together to Improve Glycemic Control in Hispanic Adults Diabetes

NCT03463629
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Specialized multidisciplinary diabetes team (SMDT) approach, Traditional model of care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 23, 2026, 1:27 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

NCT00821977
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
141
States / cities
Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 23, 2026, 1:27 PM EDT